Skip to Content
Merck
CN
  • c-Met in esophageal squamous cell carcinoma: an independent prognostic factor and potential therapeutic target.

c-Met in esophageal squamous cell carcinoma: an independent prognostic factor and potential therapeutic target.

BMC cancer (2015-06-04)
Yohei Ozawa, Yasuhiro Nakamura, Fumiyoshi Fujishima, Saulo J A Felizola, Kenichiro Takeda, Hiroshi Okamoto, Ken Ito, Hirotaka Ishida, Takuro Konno, Takashi Kamei, Go Miyata, Noriaki Ohuchi, Hironobu Sasano
ABSTRACT

c-Met is widely known as a poor prognostic factor in various human malignancies. Previous studies have suggested the involvement of c-Met and/or its ligand, hepatocyte growth factor (HGF), in esophageal squamous cell carcinoma (ESCC), but the correlation between c-Met status and clinical outcome remains unclear. Furthermore, the identification of a novel molecular therapeutic target might potentially help improve the clinical outcome of ESCC patients. The expression of c-Met and HGF was immunohistochemically assessed in 104 surgically obtained tissue specimens. The correlation between c-Met/HGF expression and patients' clinicopathological features, including survival, was evaluated. We also investigated changes in cell functions and protein expression of c-Met and its downstream signaling pathway components under treatments with HGF and/or c-Met inhibitor in ESCC cell lines. Elevated expression of c-Met was significantly correlated with tumor depth and pathological stage. Patients with high c-Met expression had significantly worse survival. In addition, multivariate analysis identified the high expression of c-Met as an independent prognostic factor. Treatment with c-Met inhibitor under HGF stimulation significantly inhibited the invasive capacity of an ESCC cell line with elevated c-Met mRNA expression. Moreover, c-Met and its downstream signaling inactivation was also detected after treatment with c-Met inhibitor. The results of our study identified c-Met expression as an independent prognostic factor in ESCC patients and demonstrated that c-Met could be a potential molecular therapeutic target for the treatment of ESCC with elevated c-Met expression.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
HGF human, recombinant, expressed in CHO cells, ≥97% (SDS-PAGE), ≥97% (HPLC)
Tantalum(V) ethoxide, packaged for use in deposition systems
Sigma-Aldrich
Tantalum(V) ethoxide, 99.98% trace metals basis